Despite promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from pharmacy benefit managers. The companies are frequently erecting barriers to access, like significant cost requirements and PA that limit patient availability. Analysts in… Read More